Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Exact Sciences Corporation, and Novartis Pharmaceuticals Corporation.
Advances In™: How the Experts Treat Oncogene-Driven Advanced NSCLC
Release Date: December 22, 2021
Expiration Date: December 22, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by educational grants from Exact Sciences Corporation, and Novartis Pharmaceuticals Corporation.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe current and emerging testing strategies for NSCLC biomarker detection in multiple lines of care
- List key actionable biomarkers that allow for personalized decision-making in the management of patients with advanced NSCLC
- Discuss strategies to facilitate the incorporation of biomarker-driven sequencing decisions among patients with advanced NSCLC
- Explain the implications of recent evidence from trials that have evaluated investigational strategies for advanced NSCLC
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
Faculty

Executive Director
Center for Thoracic Oncology, Tisch Cancer Institute
Mount Sinai, New York
Professor of Medicine and Pathology
Icahn School of Medicine
Mount Sinai, New York
Disclosures: Consultant/Advisory Board: Bristol Myers Squibb, Merck, Novartis, Sanofi/Regeneron, AstraZeneca/Daiichi, Oncocyte.

Associate Pathologist, Brigham and Women's Hospital
Chief, Thoracic Pathology
Associate Director, Center for Advanced Molecular Diagnostics
Associate Professor of Pathology, Harvard Medical School
Boston, Massachusetts
Disclosures: Research Support: Genentech; Consultant: Genentech, Lilly, EMD Serono; Shareholder: Moderna.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.